Astrana Health Third Quarter 2026 Earnings Call - ASTRANA HEALTH INC

Explicit Guidance:

• Full Year 2026: Maintains free cash flow guidance; adjusted diluted EPS of $0.71 reported as a baseline for the current quarter.
• 2027 Membership: Anticipates a 10% to 15% decline in Medicaid membership due to eligibility redeterminations, work requirements, and asset limit changes. Expects Medicare Advantage (MA) weighted average Star rating to improve modestly in 2027, remaining stable through 2028.
• 2027 Financials: Guidance to include specific revenue and EBITDA figures reflecting the 10-15% Medicaid decline and Exchange attrition; confident in delivering at least mid-teens annual adjusted EBITDA growth.
• 2027 Medical Cost Trends: Expects overall medical cost trend to remain consistent with or better than current expectations, despite specific headwinds in Medicaid and commercial drug costs.

Business-Segment Outlook:

• Medicare Advantage (MA): Growth driven by organic expansion and new partnerships; expects MA margins to remain stable into 2027 despite exclusion of certain diagnosis sources. Membership growing at a high single-digit rate organically, countering industry-wide MA footprint reductions.
• Medicaid: Expects attrition to land in the middle to high end of the 10-15% range assumed for the year; specific headwinds include the transition of UIC members to fee-for-service in 2027.
• Exchange: Membership attrition has been more favorable than the original 30-40% decline assumption; business remains approximately 3% of total revenue.
• Commercial: Membership remains stable.
• Risk Arrangements: On track to have ~82% of capitation revenue under full-risk arrangements by end of 2026 (up from 76% in 2025). Care partners' full-risk membership expected to rise to 46% from 34% year-over-year.
• Geography (Texas): Transitioning 7,000 MA members from GainShare to Global Risk and adding 3,000 under professional risk; Texas business performing ahead of plan with favorable medical trends and accelerating profitability.

Market and Competitive Outlook:

• Pricing/Reimbursement: Expects immaterial impact from the exclusion of certain diagnosis sources in the 2027 MA final rate notice.
• Competitive Position: Differentiated "flywheel" platform (Intelligence, Alignment, Delivery) expected to reduce upfront investment costs for new markets and accelerate path to profitability compared to peers.
• Provider Demand: Continued expansion of AI-powered care enablement platform; added two new clients (primary care group in CT, hospital in CA) with onboarding expected by early 2027.

Macro / Industry Outlook:

• Regulatory (MA): Monitoring 2027 MA final rate notices; confident in margin stability despite regulatory changes regarding diagnosis coding sources.
• Regulatory (Medicaid): Planning for state-level changes in 2027 including work requirements, frequent eligibility redeterminations, and asset limit adjustments.
• Economic/Cost Trends: Managing pressures from clinician-administered drug costs in commercial and higher trends in Medicaid; expects consolidated performance to continue outperforming initial 2026 assumptions.

Strategic Initiatives:

• M&A/Partnerships: Completed tuck-in acquisition of an independent physician association in Georgia (Oct 1, 2026); entered multiple new MA partnerships effective Jan 1, 2027.
• Technology Launch: Launched "Atlas," the next-generation provider-facing platform, to prioritize patients and manage high-risk events in real-time.
• Capacity/Automation: Expanding AI-orchestrated claims administration to reduce processing time from hours to minutes; aiming to deploy these capabilities across the network to capture scale benefits.
• Clinical Programs: Annual wellness visit program reaching 65% of eligible members; advancing disease management for CHF, COPD, and CKD via the "Pathways" platform.

Risks and Headwinds to Outlook:

• Membership Volatility: Potential for higher-than-anticipated attrition in Medicaid and Exchange segments due to policy changes (work requirements, eligibility redeterminations).
• Medical Cost Pressures: Specific risks include higher Medicaid medical cost trends and increased clinician-administered drug costs in the commercial segment, though currently viewed as manageable within the diversified portfolio.
• Regulatory Uncertainty: Changes in MA reimbursement rates or diagnosis coding exclusions could impact future margins, though currently deemed immaterial.
• Integration: While integrating Prospect is viewed as complete, continued execution on synergies and operational transformation remains a key focus area.

Management Tone on the Future:

• Confidence: High confidence in delivering at least mid-teens annual adjusted EBITDA growth for 2027.
• Progress: Views current execution as validating the investment thesis; describes Texas as a "proof point" for replicating the full-risk operating model in new markets.
• Operational Leverage: Expects meaningful further G&A leverage as AI capabilities mature and scale, with full-year G&A expected to hold near 6.2% of revenue.
• Hedges: Maintains conservative planning for Medicaid changes; acknowledges the need to balance growth investments (new markets, partnerships) with profitability and balance sheet objectives.